Θετικά πρόσημα στα περισσότερα ευρωπαϊκά χρηματιστήρια

χρέους
Brokers watch their screens at the stock market in Frankfurt, Germany, Monday, March 13, 2023. In background the curve of the German stock index DAX. (AP Photo/Michael Probst)
  • Ανοδικές τάσεις επικράτησαν σήμερα εν αναμονή του συμποσίου των κεντρικών τραπεζών στο Jackson Hole στα τέλη της εβδομάδας.
  • Η ανακοίνωση του δείκτη PMI για τις οικονομίες της Γερμανίας, Γαλλίας, Μεγάλης Βρετανίας, και ευρωζώνης, διατήρησε την επιφυλακτικότητα στους επενδυτές στο πρώτο μισό της συνεδρίασης, με το αγοραστικό ενδιαφέρον να αυξάνεται στο δεύτερο μισό αυτής, μετά και τα καλύτερα των εκτιμήσεων μακροοικονομικά νέα στις ΗΠΑ σχετικά με τις άδειες κατοικιών, και τις πωλήσεις νέων κατοικιών, αλλά και των προσδοκιών για τα οικονομικά αποτελέσματα δευτέρου τριμήνου της Nvidia σήμερα μετά το κλείσιμο του χρηματιστηρίου της Νέας Υόρκης.

Trending

 

Ο δείκτης Eurostoxx 600 έκλεισε στις 453,06 μονάδες με άνοδο 0,30%.

Στην Φρανκφούρτη ο δείκτης DAX έκλεισε στις 15.728,55 μονάδες με άνοδο 0,15%, μετατρέποντας το σήμα από strong sell σε sellμε την αντίσταση να βρίσκεται στις 16.488 μονάδες και την στήριξη στις 15.143 μονάδες.

Μεγαλύτερη άνοδος

Μεγαλύτερη πτώση

Στο Λονδίνο ο δείκτης FTSE 100 έκλεισε στις 7.322,98 μονάδες με άνοδο 0,72%, παραμένοντας με σήμα strong sellμε την αντίσταση να βρίσκεται στις 7.911 μονάδες και την στήριξη στις 6.972 μονάδες.

Μεγαλύτερη άνοδος

Μεγαλύτερη πτώση

Στο Παρίσι ο δείκτης CAC 40 έκλεισε στις 7.246,62 μονάδες με οριακά κέρδη 0,08%, παραμένοντας με σήμα strong sellμε την αντίσταση να βρίσκεται στις 7.599 μονάδες και την στήριξη στις 6.931 μονάδες.

Μεγαλύτερη άνοδος

Μεγαλύτερη πτώση

Εταιρικά νέα

Bluejay Mining said it has raised 600,000 pounds ($763,920) through a private share placing, which will be used on its wholly-owned Hammaslahti project in Finland. The Greenland and Finland-focused mining exploration company said Wednesday the shares were placed at a price of 1.0 pence each, a 15% discount on the price at yesterday’s close-of-business. The funds will be used on the Hammaslahti mine where the company is currently developing a mineral resource estimate. The proceeds will also go toward the exploration planning at the Kangerluarsuk project in Greenland. “The immediate use of these funds will position us for a productive and pivotal second half of 2023, and what we believe could be a transformational 2024,” Chief Executive Robert Edwards said.

Bradda Head said drilling results from its Basin East Extension has returned the highest single-interval grade so far, which supports the potential for a significant expansion at the project. The North America-focused lithium explorer said Wednesday that the drilling program found better-than-expected clay thickness, which has shown potential for material resource expansion at the project. “These latest assays solidify the resource expansion potential at Basin and the high-grade lithium intercepts encountered in the recent drilling campaign demonstrate the exceptional potential of the project,” Chief Executive Charles FitzRoy said.

Roche Holding said data from a late-stage clinical trial evaluating a lung-cancer treatment has been inadvertently disclosed, and that the study will continue until a final analysis for overall survival has been completed. The Swiss pharmaceutical giant said Wednesday that there was an inadvertent disclosure of the second interim analysis of the phase 3 trial when interim results for the overall survival rate–a primary goal of the trial–weren’t mature.

The study is continuing and remains blinded to patients and investigators, the company said. The trial evaluates immunotherapy tiragolumab in combination with antibody Tecentriq against Tecentriq alone as an initial treatment for people with a particular case of advanced or metastatic non-small cell lung cancer, Roche said. The interim results showed an estimated median overall survival of 22.9 months for patients who received the combination, against 16.7 months for those who were in the monotherapy arm, the company said. The combination of tiragolumab plus Tecentriq was well tolerated, it said.

Costain Group said that first-half pretax profit fell on the back of higher costs and that it is considering the payment of an interim dividend. The infrastructure company reported on Wednesday a pretax profit of 8.5 million pounds ($10.8 million) for the six months, down from GBP11.2 million reported the same period a year ago. Adjusted operating profit–one of the company’s preferred metrics–rose 7.1% to GBP15.0 million, supported by increasing volumes and margin in natural resources business, and benefits from its transformation program. Revenue slightly fell to GBP664.4 million from GBP665.2 million. The company backed its 2023 expectations and said that it remains on track to deliver an adjusted operating margin run-rate of 3.5% during 2024 and 4.5% during 2025. The company said that the board is considering and interim dividend payment, with an announcement expected to be made soon.

U.K. energy regulator Ofgem has fined Morgan Stanley & Co. International 5.4 million pounds ($6.9 million) for failing to record and keep electronic trading communications between January 2018 and March 2020. The regulator said Wednesday that Morgan Stanley admitted the breaches and fully co-operated with it to settle the case. It received a 30% discount to the penalty for settling. Moran Stanley has taken steps to ensure that the breaches don’t happen again, including enhanced staff training and strengthening its internal systems and controls. “It is unacceptable that MSIP failed to prevent electronic communications which could not be recorded or retained. It risks a significant compromise of the integrity and transparency of wholesale energy markets,” Regulatory Director of Enforcement and Emerging Issues at Ofgem, Cathryn Scott said.

GSK said that a trial showed 100% efficacy of its vaccine in the prevention of shingles in adults aged 50 and over in China. The British pharmaceutical giant said on Wednesday that the post-license phase IV trial had no cases of shingles, known as herpes zoster, reported among the participants who received the vaccine.The study was the first efficacy trial of Shingrix in China and showed results consistent with the phase three trials. The study included almost 6,000 participants, it added. The results will be submitted for publication in a scientific journal later this year, GSK added.

Τα παραπάνω εκφράζουν προσωπικές απόψεις, και σε καμία περίπτωση δεν αποτελούν προτροπή για αγορά, πώληση ή διακράτηση οποιασδήποτε κινητής αξίας.

 

Ακολουθήστε το στο Google News και μάθετε πρώτοι όλες τις ειδήσεις
Δείτε όλες τις τελευταίες Ειδήσεις από την Ελλάδα και τον Κόσμο, στο